Entheon Adopts Semi-Annual Reporting

Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) (" Entheon " or the " Company ") announces that it has elected to participate in the Coordinated Blanket Order 51-933 – Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the " Blanket Order "), issued by the Canadian Securities Administrators, and adopts semi-annual financial reporting. This news release is being filed pursuant to the Blanket Order. The Blanket Order is a pilot program that permits eligible venture issuers to voluntarily move from quarterly to semi-annual financial reporting. The Company has determined that it meets the eligibility criteria under the Blanket Order, including that it is a venture issuer, has annual revenue of less than $10 million, has a disclosure record of over 12 months, and has filed all required periodic and timely disclosure documents. As a result of this election, the Company will file interim financial reports and associated management's discussion and analysis ("MD&A") on a semi-annual basis, rather than quarterly. The Company's fiscal year-end is November 30 and will continue to file annual audited financial statements (due within 120 days of November 30). The Company will continue to remain subject to timely disclosure requirements and will continue to report all material changes and significant developments in accordance with National Instrument 51-102 – Continuous Disclosure Obligations. Under the Blanket Order, the Company will be exempt from filing interim financial reports and associated MD&A for its first and third quarters. The initial period for which the Company will not file a quarterly interim financial report and associated MD&A will be for the three and nine months ended August 31, 2026. The Company will file its next financial report for the year ended November 30, 2026 (due within 120 days of November 30, 2026). Should the Company cease to continue participating in the Blanket Order, it will announce it in a future news release. About Entheon Biomedical Corp. Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders. On Behalf of the Board of Directors, Timothy Ko, CEO and Director For more information, please contact the Company at: Entheon Biomedical Corp. Timothy Ko, CEO 1 (604) 562-3932 [email protected] https://entheonbiomedical.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/314082 Source: Entheon Biomedical Corp.